Matritech Announces New Web Site Home Page: www.matritech.com
Browsers Can Easily Access Current Information on Bladder Cancer Treatment, Diagnosis and Monitoring
NEWTON, Mass., May 7 /PRNewswire/ -- Matritech, Inc., (Nasdaq:NMPS) announced its new Web site at www.matritech.com.
The site is divided into four major sections for easy browsing including: An overview on bladder cancer diagnosis, treatment and monitoring; updates on nuclear matrix protein (NMP) technology; Matritech product information; and corporate background.
``Matritech's new Web site will give the medical and laboratory communities as well as patients and families current information on bladder cancer, nuclear matrix protein technology, the NMP22(R) Test Kit for bladder cancer, and our company. Our objective is to build awareness of NMP testing and ultimately improve the management of cancer patients,'' said David Corbet, Matritech's President and Chief Operating Officer.
Matritech, Inc., based in Newton, Mass., is using its proprietary nuclear matrix protein (NMP) technology, discovered at the Massachusetts Institute of Technology (MIT) and licensed exclusively to Matritech, to develop and commercialize innovative serum-, cell- and urine-based NMP diagnostics that enable physicians to reliably detect and monitor the presence of bladder, colorectal, cervical, breast, lung and prostate cancers. In July 1996, the Food and Drug Administration (FDA) approved Matritech's NMP22 Test Kit for sale in the United States. The test is the only quantitative, non-invasive urine test for bladder cancer that can identify patients at risk for recurrence with a high degree of accuracy. Until NMP22, bladder cancer patients have been managed by examining cells from the bladder shed
in urine (cytology) or scoping the inside of the bladder using a fiber-optic device (cystoscopy).
SOURCE: Matritech, Inc. |
